AFX:XETRA-Carl Zeiss Meditec AG (EUR)

COMMON STOCK | Medical Instruments & Supplies | XETRA

Last Closing Price

EUR 170.35

Change

0.00 (0.00)%

Market Cap

EUR 15.24B

Volume

0.05M

Avg Analyst Target

EUR 170.75 (+0.23%)

Avg User Target

EUR
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Carl Zeiss Meditec AG operates as a medical technology company in Germany, the United States, Japan, France, Spain, India, the United Kingdom, Turkey, North Africa, and internationally. It operates in two segments, Ophthalmic Devices and Microsurgery. The Ophthalmic Devices segment offers optical biometers, ophthalmic surgical microscopes, phacoemulsification/vitrectomy devices, intraocular lenses, and ophthalmic viscoelastic products for the diagnosis and treatment of ophthalmic diseases in the field of cataract and retinal surgery. This segment also offers optical coherence tomography devices, perimeters, fundus cameras, slit lamps, and therapeutic and refractive lasers for the diagnosis and treatment of various eye diseases, such as refraction, glaucoma, and other retinal diseases, as well as FORUM, an eye care data management system. The Microsurgery segment provides surgical microscopes and visualization solutions for neuro, spinal, dental, and plastic and reconstructive surgeries, as well as for ear, nose, and throat surgery; products for surgical treatment of tumors or vascular diseases, such as aneurysms; and INTRABEAM, a intraoperative radiotherapy device. Carl Zeiss Meditec AG serves ophthalmologists and optometrists, as well as physicians and surgeons in hospitals and outpatient surgery centers. The company was founded in 2002 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG is a subsidiary of Carl Zeiss AG. Address: Goschwitzer Strasse 51-52, Jena, Germany, 07745

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-10-24 )

Largest Industry Peers for Medical Instruments & Supplies

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
SRT:XETRA Sartorius Aktiengesellschaft

N/A

EUR39.18B 176.19 39.42
SRT3:XETRA Sartorius Aktiengesellschaft

N/A

EUR39.18B 169.90 39.42
BTL:XETRA Baxter International Inc

N/A

EUR35.34B 37.67 15.67
GXI:XETRA Gerresheimer AG

N/A

EUR2.44B 28.14 11.94

ETFs Containing AFX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Medical Instruments & Supplies)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 56.43% 60% D- 93% A
Dividend Return 0.46% 80% B- 12% F
Total Return 56.89% 60% D- 93% A
Trailing 12 Months  
Capital Gain 43.51% 60% D- 80% B-
Dividend Return 0.42% 60% D- 8% F
Total Return 43.93% 60% D- 80% B-
Trailing 5 Years  
Capital Gain 394.41% 50% F 97% A+
Dividend Return 5.86% 67% D+ 26% F
Total Return 400.28% 50% F 97% A+
Average Annual (5 Year Horizon)  
Capital Gain 40.04% 60% D- 95% A
Dividend Return 0.72% 80% B- 65% D
Total Return 40.76% 60% D- 95% A
Risk Return Profile  
Volatility (Standard Deviation) 27.50% 60% D- 27% F
Risk Adjusted Return 148.21% 60% D- 98% A+
Market Capitalization 15.24B 40% F 87% B+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Medical Instruments & Supplies)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 64.43 60% D- 16% F
Price/Book Ratio 9.65 60% D- 13% F
Price / Cash Flow Ratio 85.34 20% F 3% F
EV/EBITDA 41.26 20% F 11% F
Management Effectiveness  
Return on Equity 10.51% 40% F 51% F
Return on Invested Capital 7.96% 40% F 65% D
Return on Assets 6.83% 60% D- 78% C+
Debt to Equity Ratio 6.11% 100% A+ 88% B+
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.38 60% D- 92% A-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Ratings

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low debt

The company is less leveraged than its peers ,, and is among the top quartile, which makes it more flexible. However, do check the news and look at its sector. Sometimes this is low because the company is not growing and has no growth potential.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

Superior Dividend Growth

This stock has shown top quartile dividend growth in the previous 5 years compared to its sector

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Poor return on equity

The company management has delivered below median return on equity in the most recent 4 quarters compared to its peers.

Poor capital utilization

The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.